The European Medicines Agency's Committee for Medicinal Products for Human Use voted against Puma Biotechnology Inc.'s (Nasdaq: PBYI) Marketing Authorization Application for neratinib to treat early stage HER2-positive breast cancer sending the stock price crashing $26.20 to close at $64.70.
European agency votes against Puma Biotechnology
January 24, 2018 at 16:15 PM EST
